Epigenetic Age Acceleration and All-Cause Mortality: A 15-Year Prospective Cohort

Researchers followed 4,218 adults aged 50–75 for a median of 15.2 years, measuring epigenetic age via the GrimAge clock at baseline. The primary outcome was all-cause mortality; secondary outcomes included cardiovascular and cancer-specific mortality.

• Participants in the highest quartile of epigenetic age acceleration had 1.62× higher all-cause mortality (95% CI: 1.38–1.91) compared to the lowest quartile.
• The association persisted after adjustment for smoking, BMI, physical activity, and comorbidities.
• Cardiovascular mortality showed the strongest association (HR 1.84), followed by cancer mortality (HR 1.51).
• Epigenetic age acceleration at baseline was a stronger predictor than chronological age alone in multivariate models.

This study strengthens the case for incorporating epigenetic clocks into preventive longevity assessments. While not yet standard-of-care, GrimAge acceleration may help physicians identify patients who would benefit from intensified cardiovascular and metabolic surveillance — particularly those whose chronological age understates their physiological risk.

At KCM, we interpret epigenetic age data within a broader diagnostic context. A single accelerated clock reading does not mandate intervention — but it may shift screening intervals, prioritize advanced imaging, and inform conversations about modifiable risk factors with greater urgency.